The specter of generic competition has long loomed above copyright’s famous drug, Viagra, triggering questions about the outlook of connected pharmaceutical portfolios. While first times saw substantial profits, the intellectual property expiration has created the door for less expensive copies, potentially diminishing profitability and posing a